New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.
Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...
Obinutuzumab was superior to placebo for systemic lupus erythematosus in a phase 3 trial, significantly improving SRI-4 response rates.
The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.
Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
Decision aids (DA) are one of the many approaches used to help increase patient knowledge of their disease or illness and improve provider/patient communication, which can contribute to more favorable ...
Novel allogeneic CAR-T therapy demonstrates durable remission and immune-reset mechanism in systemic lupus erythematosusBOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Maureen McMahon, ...
Credit: Getty Images Understanding the underlying mechanisms and immunological dysfunction of SLE is essential to appreciate its diverse clinical manifestations and guide effective diagnosis and ...
Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results